Pharmacokinetics and clinical studies of ioglicinate, a new contrast medium for intravenous urography.
The new amino acid-bound contrast medium ioglicinate was first of all studied in respect of its pharmacokinetics in comparison to iothalamate and amidotrizoate in groups of 4 patients. The distribution volume was very similar for all 3 substances. Ioglicinate was found to have the shortest half-life. The elimination of the contrast media studied was mainly via the kidneys. The plasma protein binding of ioglicinate was again lower than that of amidotrizoate and iothalamate. These good experimental results were confirmed for ioglicinate in respect of the tolerance and opacification in a subsequently conducted clinical double-blind study in groups of 50 patients in comparison with iothalamate.
D000368:Aged; D001798:Blood Proteins / Q000378:metabolism; D003287:Contrast Media; D006801:Humans; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011485:Protein Binding; D013997:Time Factors
D001798:Blood Proteins; D003287:Contrast Media; D007483:Iothalamic Acid; C016525:ioglicic acid